Engaging Investigators early and proactively participating in a clinical trial in the preliminary planning and feasibility phases of a study. This method aids in ensuring site readiness, protocol viability, and alignment with actual clinical workflows. Sponsors and CROs can improve trial efficiency, compliance, and data quality by implementing investigator insights early on. This allows them to anticipate operational challenges, improve recruitment strategies, and cultivate stronger site relationships.

Early engagement of investigators within the top-tier competition of clinical research has become a necessity in the North American region. This will facilitate meeting the deadlines within the study start-up timelines. With quality, compliance, and site engagement in mind, there is a greater need to balance speed and value. It is better to bring on board investigators who will be an integral part of the study as early as possible, since this assists in more than just collaboration, eases feasibility, and lays a strong foundation for running the study successfully.

The United States and Canada are home to about 42-45% of the total clinical trials. This figure is an outright testimonial to the fact that America and Canada are among the most sought regions for clinical research. The region’s unparalleled diversity in the population of patients, sophisticated healthcare systems, and rigorous infrastructure are additional boons for the region. The unmet medical need driven by a high prevalence of oncological, cardiovascular, and infectious diseases is are strong factors that motivate sponsors to undertake aggressive drug development strategies.

The start-up challenge in North America

Canada and the United States are still key players in clinical research and continue to host roughly 45% of the ongoing global clinical trials. With much of the clinical research infrastructure available in the United States, including regulatory sophistication and a large pool of clinical investigators, there are still some operational challenges facing sponsors and CROs to get studies underway.

Some of the issues that these CROs face include the high regulatory competition at cross-functional levels, the competition between sites, and the multi-layered challenges in communication across key stakeholders.

• Intricate regulatory frameworks associated with submissions and ethics are outlined by IRBS.
• Tough competition for sites and investigators with requisite experience.
• Fragmented communication between sponsors, CROs, and sites
• Holds in feasibility studies, contracting, and site activation

It has been noted by sponsors who retain the services of investigators for site evaluation and activation in the pre-study phase that they are more likely to experience faster activation and are more likely to comply with the protocol.

Read our article on the key trends shaping the future of clinical trial sites and investigator networks across North America.

Why early investigator engagement matters

Including clinical site investigators before finalizing the protocol provides important benefits for trial feasibility, compliance, and overall success. Investigators have firsthand knowledge of patient populations, site capabilities, and logistical constraints. This insight helps to refine inclusion and exclusion criteria, visit schedules, and endpoint assessments to ensure they reflect real-world conditions.

Their early input lowers the chances of protocol amendments, recruitment delays, and procedural issues, while creating stronger site engagement and ownership. Furthermore, involving investigators from the beginning makes sure the protocol meets Good Clinical Practice (GCP) guidelines and quality-by-design principles. This approach improves regulatory acceptance and reduces risks during inspections.

1. Evaluation protocol feasibility 

Clinical investigators offer firsthand knowledge if the trial is executable at their site.

• Refine inclusion/exclusion criteria
• Adjust visit schedules and procedures
• Align endpoints with clinical practice

2. Engagement investigators early accelerated feasibility & site selection

With the help of early engagement of investigators, utilizing pre-qualification strategies based on an investigator’s interest, experience, and patient access, early engagement helps to streamline the site-scouting process and limits the broad feasibility surveys to the already pre-identified high-potential sites.

3. Improved contracting & regulatory compliance

With early engagement, strategic study integration allows for streamlined document processing, which in turn enables proactive team engagement. When an investigator is included as an active participant during the protocol development or feasibility stage, the clarity on expectations, timelines, and site responsibilities greatly helps. This ownership results in:

• Responsive submissions to the IRB
• Agility in budget negotiations
• Compliance timelines for regulatory document completion
• Proactive Strategic Planning

4. Enhanced recruitment planning

Investigators can help forecast realistic enrollment targets, identify referral networks, and flag potential recruitment barriers. Sponsors can then build tailored recruitment strategies and allocate resources more effectively.

To learn more about early engagement strategies, please click here.

Practical approaches to early engagement

Sponsors and CROs can adopt several tactics to engage investigators early in the study lifecycle:

Structured outreach

Utilize targeted outreach campaigns, including email, webinars, and investigator portals, to introduce the study concept and gauge interest. Include:

• Protocol synopsis
• Study timelines
• Site expectations and benefits

Investigational advisory boards

Form advisory boards during protocol development to gather input from experienced investigators. This fosters ownership and alignment with study goals.

Feasibility interviews

Go beyond surveys, conduct one-on-one interviews to assess site capabilities, patient pool, and operational readiness. This qualitative data is often more actionable than checkbox responses.

Early CDA & pre-qualification

Initiate confidentiality agreements and pre-qualification steps early to streamline downstream contracting and document exchange.

Digital collaboration tools

Use platforms like CTMS, Clinical Data Management software, IWRS/IVRS, eCOA, Site feasibility platforms, centralized communication, document sharing, and milestone tracking.

Real-world impact: Metrics that matter

Sponsors that prioritize early investigator engagement report measurable improvements in key performance indicators (KPIs):

Metric	Improvement
Site identification time	↓ 53%
Non-enrolling sites	↓ 50%
First patient in (FPI)	↑ 25% likelihood
Last patient in (LPI)	↑ 21% likelihood
Site activation time	↓ 50%
Document error rates	↓ to 0.1% (well below industry benchmarks)

These metrics translate into faster trial execution, reduced costs, and improved data quality. Please do visit to learn more details about the early engagement program.

Case study: Oncology trial in North America

A mid-sized biotech sponsor preparing to launch a Phase III oncology trial across North America had previously encountered significant delays in site activation during an earlier study. Drawing lessons from that experience, the sponsor adopted a proactive early engagement strategy for the new trial, aimed at streamlining feasibility, accelerating regulatory readiness, and fostering stronger site relationships.

• Conducted protocol review sessions with 15 oncology investigators
• Used structured feasibility interviews instead of generic surveys
• Shared draft budget and regulatory timelines upfront
• Provided early access to the eTMF and training materials

Outcome:

• 80% of sites were activated within the targeted scheduled time of IRB approval
• Enrollment began 3 weeks ahead of schedule
• No major protocol deviations in the first 3 months

This proactive approach not only accelerated start-up but also strengthened sponsor-site relationships.

Strategic considerations for sponsors

To gain the most value from early investigator involvement, sponsors need to engage with them at the site feasibility and protocol development stages so that operational workability and compliance with regulations are met. This collaboration builds confidence, constructive involvement in planning, and allows the sponsor to gain feedback from the investigators on the local demographics, competing studies, and studies that the site is capable of offering. This, in turn, results in effective recruitment timelines, protocol adherence, data collection, and overall study rigor.

Through properly organized investigator meetings and ongoing dialogue, sponsors can optimize site readiness, streamline deviation accrual, and set up the study for quality at the work’s outset.

• Communications from clinical operations, medical affairs, and regulatory affairs should be unified for a single sponsor for interdisciplinary collaboration, fostering engagement with a single point of contact for each cross-disciplinary team.
• Define subgroups for outreach campaigns based on their past performance metrics, geographic relevance, and their therapeutic area expertise as primary, secondary, and tertiary contacts.
• Provide pertinent study information, applicable clinical insights, comprehensive training, and ongoing support to promote investigator ownership.
• Track responsiveness and preparedness using CRM and CTMS tools.

Common pitfalls to avoid

While early engagement is powerful, it must be executed thoughtfully. Common missteps include engaging investigators too late in the protocol development process, offering limited transparency around timelines and expectations, and failing to tailor feasibility assessments to site-specific realities. Sponsors may also overlook the importance of two-way communication, resulting in disengaged sites and operational blind spots.

• Engaging too broadly without clear selection criteria
• Overpromising timelines or protocol flexibility
• Failing to follow up after initial outreach
• Not integrating investigator feedback into protocol design

Sponsors must treat early engagement as a strategic partnership, not just a checkbox in the start-up process.

The future of investigational engagement

As clinical trials go more remote and digital, getting investigators involved early is becoming smarter, tech-driven, and all about the patient. Instead of just checking if a study plan works, researchers will help design the whole thing to fit remote check-ins, flexible timing, and different kinds of people.

Tech tools like site finders, study plan models, and up-to-the-minute recruitment numbers will give researchers more say in running the study smoothly. Also, study organizers might pick sites that already use tech well and work well with others, turning one-off choices into lasting teamwork.

Training will change, too, with online lessons and AI study simulations made just for each site, so they feel more in charge from the start.

Trends to watch include:

• AI site picking: Using smart data to find top-notch research sites.
• Online planning tools: Checking sites and running study tests from afar.
• Investigator groups: Building lasting ties through shared learning.
• Real-time dashboards: Tracking engagement metrics and readiness across global sites.

These innovations will further compress timelines and improve trial outcomes.

Conclusion

Engaging investigators early is not just a tactical move; it’s a strategic enabler of faster, smarter, and more compliant study start-up in North America. By fostering collaboration, aligning expectations, and leveraging technology, sponsors can transform the start-up phase from a bottleneck into a launchpad. Whether you’re managing oncology, ophthalmology, or any other therapeutic area, early engagement is a proven path to operational excellence.

---

Are you aiming to speed up trial start-up and boost protocol feasibility by strategically involving North American investigators from the outset?

If you’re considering early engagement strategies for your clinical trial development program, fill out the form below, and our team will reach out soon to discuss how we can help you achieve your goals.

---